Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1986 Feb;144(2):165–168.

In Vitro Prostacyclin Production in the Hemolytic-Uremic Syndrome

Richard L Siegler 1, Jean B Smith 1, Michael B Lynch 1, S F Mohammad 1
PMCID: PMC1306552  PMID: 3754077

Abstract

Reports from Europe suggest that the hemolytic-uremic syndrome is associated with an impaired ability to produce prostacyclin (prostaglandin [PG] I2), a potent inhibitor of platelet aggregation and thrombus formation. In comparing the production of PGI2 by cultured endothelial cells using serum obtained from 22 children with the hemolytic-uremic syndrome with values obtained using serum from 22 normal children, we found that cultured endothelial cells produced less PGF1α (the stable metabolite of PGI2) when incubated with affected serum. The relationship of this observation to the pathogenesis of the hemolytic-uremic syndrome is unclear.

Full text

PDF
165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bale J. F., Jr, Brasher C., Siegler R. L. CNS manifestations of the hemolytic-uremic syndrome. Relationship to metabolic alterations and prognosis. Am J Dis Child. 1980 Sep;134(9):869–872. doi: 10.1001/archpedi.1980.02130210053014. [DOI] [PubMed] [Google Scholar]
  2. Brasher C., Siegler R. L. The hemolytic-uremic syndrome. West J Med. 1981 Mar;134(3):193–197. [PMC free article] [PubMed] [Google Scholar]
  3. Byrnes J. J., Lian E. C. Recent therapeutic advances in thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 1979 Winter;5(3):199–215. doi: 10.1055/s-0028-1087153. [DOI] [PubMed] [Google Scholar]
  4. Cattran D. C. Adult hemolytic-uremic syndrome: successful treatment with plasmapheresis. Am J Kidney Dis. 1984 Jan;3(4):275–279. doi: 10.1016/s0272-6386(84)80045-1. [DOI] [PubMed] [Google Scholar]
  5. Chamone D. A., Proesmans W. C., Monnens L. A., Binda ki Muaka P., Vermylen J. G. Reversible deficient prostacyclin release in childhood hemolytic uremic syndrome. Int J Pediatr Nephrol. 1982 Mar;3(1):13–16. [PubMed] [Google Scholar]
  6. Chen Y. C., McLeod B., Hall E. R., Wu K. K. Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura. Lancet. 1981 Aug 8;2(8241):267–269. doi: 10.1016/s0140-6736(81)90522-5. [DOI] [PubMed] [Google Scholar]
  7. Feldhoff C. M., Luboldt W., Bussmann K., Schrör K. Plasma exchanges in frequently recurrent hemolytic-uremic syndrome in a child. Int J Pediatr Nephrol. 1983 Dec;4(4):239–242. [PubMed] [Google Scholar]
  8. Furuse A., Hattori S., Matsuda I. A case of hemolytic uremic syndrome with high concentration of circulating immune complex in the initial stage. Int J Pediatr Nephrol. 1983 Jun;4(2):123–126. [PubMed] [Google Scholar]
  9. Gonzalo A., Mampaso F., Gallego N., Bellas C., Segui J., Ortuño J. Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue. Clin Nephrol. 1981 Oct;16(4):193–199. [PubMed] [Google Scholar]
  10. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. doi: 10.1172/JCI107470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jørgensen K. A., Pedersen R. S. Familial deficiency of prostacyclin production stimulating factor in the hemolytic uremic syndrome of childhood. Thromb Res. 1981 Feb 1;21(3):311–315. doi: 10.1016/0049-3848(81)90168-7. [DOI] [PubMed] [Google Scholar]
  12. Koster F., Levin J., Walker L., Tung K. S., Gilman R. H., Rahaman M. M., Majid M. A., Islam S., Williams R. C., Jr Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med. 1978 Apr 27;298(17):927–933. doi: 10.1056/NEJM197804272981702. [DOI] [PubMed] [Google Scholar]
  13. Levin M., Elkon K. B., Nokes T. J., Buckle A. M., Dillon M. J., Hardisty R. M., Barratt T. M. Inhibitor of prostacyclin production in sporadic haemolytic uraemic syndrome. Arch Dis Child. 1983 Sep;58(9):703–708. doi: 10.1136/adc.58.9.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moncada S., Higgs E. A., Vane J. R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977 Jan 1;1(8001):18–20. doi: 10.1016/s0140-6736(77)91655-5. [DOI] [PubMed] [Google Scholar]
  15. Ray C. G., Tucker V. L., Harris D. J., Cuppage F. E., Chin T. D. Enteroviruses associated with the hemolytic-uremic syndrome. Pediatrics. 1970 Sep;46(3):378–388. [PubMed] [Google Scholar]
  16. Remuzzi G., Marchesi D., Cavenaghi A. E., Livio M., Donati M. B., de Gaetano G., Mecca G. Bleeding in renal failure: a possible role of vascular prostacyclin (PGI2). Clin Nephrol. 1979 Sep;12(3):127–131. [PubMed] [Google Scholar]
  17. Remuzzi G., Marchesi D., Misiani R., Mecca G., de Gaetano G., Donati M. B. Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thromb Res. 1979;16(3-4):517–525. doi: 10.1016/0049-3848(79)90098-7. [DOI] [PubMed] [Google Scholar]
  18. Remuzzi G., Misiani R., Marchesi D., Livio M., Mecca G., de Gaetano G., Donati M. B. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet. 1978 Oct 21;2(8095):871–872. doi: 10.1016/s0140-6736(78)91573-8. [DOI] [PubMed] [Google Scholar]
  19. Remuzzi G., Misiani R., Marchesi D., Livio M., Mecca G., de Gaetano G., Donati M. D. Treatment of the hemolytic uremic syndrome with plasma. Clin Nephrol. 1979 Dec;12(6):279–284. [PubMed] [Google Scholar]
  20. Saba H. I., Saba S. R., Blackburn C. A., Hartmann R. C., Mason R. G. Heparin neutralization of PGI2: effects upon platelets. Science. 1979 Aug 3;205(4405):499–501. doi: 10.1126/science.377493. [DOI] [PubMed] [Google Scholar]
  21. Smith J. B., Jubiz W. OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro. Prostaglandins. 1981 Sep;22(3):353–363. doi: 10.1016/0090-6980(81)90098-8. [DOI] [PubMed] [Google Scholar]
  22. Spencer C. D., Crane F. M., Kumar J. R., Alving B. M. Treatment of postpartum hemolytic uremic syndrome with plasma exchange. JAMA. 1982 May 28;247(20):2808–2809. [PubMed] [Google Scholar]
  23. Stuart M. J., Spitzer R. E., Coppe D. Abnormal platelet and vascular prostaglandin synthesis in an infant with hemolytic uremic syndrome. Pediatrics. 1983 Jan;71(1):120–124. [PubMed] [Google Scholar]
  24. Wiles P. G., Solomon L. R., Lawler W., Mallick N. P., Johnson M. Inherited plasma factor deficiency in haemolytic-uraemic syndrome. Lancet. 1981 May 16;1(8229):1105–1106. doi: 10.1016/s0140-6736(81)92275-3. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES